Endurant Capital Management LP Aerie Pharmaceuticals Inc Transaction History

Endurant Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 15, 2018	SELL	$51.15 - $61.0 $2.32 Million - $2.77 Million	-45,366 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$50.85 - $65.1 $601,148 - $769,612	-11,822 Reduced 20.67%	45,366 $2.71 Million
Q3 2017 Nov 14, 2017	BUY	$48.6 - $60.1 $2.78 Million - $3.44 Million	57,188	57,188 $2.78 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.